Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Attomey's Docket No. 09531-016002	Application No. 10/031,005	
		Applicant Gary L. Nelsestuen		
		Filing Date October 29, 2001	Group Art Unit 1656	

			U.S. Pate	ent Documents			· · · · · · · · · · · · · · · · · · ·
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
B	AA	6,806,063	10/19/2004	Pedersen et al.	~	_	
	AB						

	Foreig	n Patent Doo	cuments or F	ublished Foreign	Patent /	pplication	ns	<u> </u>
Examiner	Desig.	Document	Publication	Country or			Trans	slation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
43	AC	WO 01/58935	8/16/2001	WIPO				
	AD							

	Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner	Desig.					
Initial	ID	Document				
15	AE	GenBank® Accession No. M13132 (2/13/1996)				
#5	AF	"Docking of Tissue Factor and Factor VIIa Initiates Blood Coagulation," at http://www.sdsc.edu.IOTW/week46.96/ (1996)				
85	AG	Dickinson and Ruf, "Active Site Modification of Factor VIIa Affects Interactions of the Protease Domain with Tissue Factor," J. Biol. Chem., 1997, 272(32):19875-19879				
#	AH	Jurlander et al., "Recombinant Activated Factor VII (rFVIIa): Characterization, Manufacturing, and Clinical Development," Semin. Thromb. Hemos., 2001, 27(4):373-383				
45	AI	Leff, "Genetically Stripped-Down Factor VIII Corrects Bleeding Disorder in Hemophiliac Mice," BioWorld Today, 1997, 8(209):1,6				
H	AJ	Martinez et al., "Underdecarboxlyation of Vitamin K-Dependent Proteins: Occasionally Severe, Possibly Universal," Proceedings of the 49th ASMS Conference on Mass Spectrometry and Allied Topics, May 27-31, 2001, Chicago, Illinois, 2 pgs.				
115	AK	Nelsestuen et al., "Elevated Function of Blood Clotting Factor VIIa Mutants That Have Enhanced Affinity for Membranes," J. Biol. Chem., 2001, 276(43):39825-39831				
th	AL	Ruf et al., "Importance of Factor VIIa Gla-Domain Residue Arg-36 for Recognition of the Macromolecular Substrate Factor X Gla-Domain," Biochemistry, 1999, 38:1957-1966				
B	AM	Sakai et al., "The γ-Carboxyglutamic Acid Domain of Human Factor VIIA is Essential for Its Interaction with Cell Surface Tissue Factor," J. Biol. Chem., 1990, 265(4):1890-1894				
#5	AN	Thim et al., "Amino Acid Sequence and Posttranslational Modification of Human Factor VIIa from Plasma and Transfected Baby Hamster Kidney Cells," Biochemistry, 1988, 27:7785-7793				
	AO					

Examiner Signature /// /	Date Considered
TAM S	8-9-06
EXAMINER: Initials citation considered. Draw line through citation if	not in conformance and not considered. Include copy of this form with
next communication to applicant.	

Substitute (Medified	m F	TO-1449
- Ug	_	

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 09531-016002

Application No. 10/031,005

Information Disclosure Statement
by Applicant
(Use several sheets if necessary)

Applicant
Gary L. Nelsestuen

Filing Date

Group Art Unit

October 29, 2001

1656

WATER ADE	_		U.S. Pate	nt Documents			
Examir Initia		Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
14	S AA	4,784,950	11/15/1988	Hagen et al.			
1	AB	4,904,584	2/27/1990	Shaw		_	
	AC	5,041,376	8/20/1991	Gething et al.	_		
	AD	5,180,583	1/19/1993	Hedner	_	-	·
	AE	5,225,537	7/6/1993	Foster	1		
	AF	5,460,950	10/24/1995	Barr et al.	_	_	
	AG	5,648,254	7/15/1997	Mulvihill et al.	_		
	AH	5,891,843	4/6/1999	Turecek et al.			
	AI	5,965,425	10/12/1999	Barr et al.	_		
	AJ	5,986,079	11/16/1999	Barr et al.	_		·
	AK	6,013,620	1/11/2000	Turecek et al.			
	AL	6,100,061	8/8/2000	Reiter et al.	_		
	AM	6,423,826	7/23/2002	Nelsestuen et al.	-		
	AN	6,475,725	11/5/2002	Reiter et al.			
	AO	6,693,075	2/17/2004	Nelsestuen	_		
	AP	6,747,003	6/8/2004	Nelsestuen			
	AQ	6,762,286	7/13/2004	Nelsestuen		_	
	AR	6,903,069	6/7/2005	Pingel et al.	_		
	AS	2003/0100506	11/18/2002	Nelsestuen			
	АТ	2003/0100740	11/15/2002	Persson et al.	_		
	AU	2003/0104978	9/13/2001	Persson et al.	-	_	
	AV	2003/0211094	12/30/2002	Nelsestuen	_		
H	SAW	2003/0211460	12/30/2002	Nelsestuen	-		

	Foreign	Patent Docun	nents or Pub	lished Foreign	Patent /	Application	ns
Examiner	Desig.	Document	Publication	Country or	Class	Subclass	Translation
Examiner Sign		14/2	1		7-5-0		
next communi	Initials citation ication	considered. Draw line icant.	through citation if no	ot in conformance and no	ot considered	i. Include copy o	f this form with
					Subs	stitute Disclosure	Form (PTO-1449)

Substitute Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office

(Modified)

Information Disclosure Statement by Applicant

(Use several sheets if necessary)

(37 CFR § \$8(b))

Attorney's Docket No. 09531-016002

Application No. 10/031,005

Applicant

Gary L. Nelsestuen

Filing Date Group Art Unit October 29, 2001

Yes No

NT & TRACE						Yes	No
145	AX	WO 91/11514	8/8/1991	WIPO			
	AY	WO 92/15686	9/17/1992	WIPO			
	AZ	WO 94/27631	12/8/1994	WIPO			
	AAA	WO 96/00577	1/11/1996	WIPO			
	ABB	WO 98/32466	7/30/1998	WIPO			
	ACC	WO 98/35026	8/13/1998	WIPO			
	ADD	WO 99/03498	1/28/1999	WIPO			
	AEE	WO 99/03887	1/28/1999	WIPO			
	AFF	WO 99/66031	12/23/1999	WIPO			
	AGG	WO 00/26230	5/11/2000	WIPO			
	АНН	WO 00/26354	5/11/2000	WIPO			
	AII	WO 00/28065	5/18/2000	WIPO			,
	AJJ	WO 00/54787	9/21/2000	WIPO			
	AKK	WO 00/66753	11/9/2000	WIPO			
	ALL	WO 01/83725	11/8/2001	WIPO			
	AMM	WO 02/02764	1/10/2002	WIPO			
	ANN	WO 02/03075	1/10/2002	WIPO			
	A00	WO 02/077218	10/3/2002	WIPO			
	APP	WO 02/22776	3/21/2002	WIPO			
	AQQ	WO 02/29025	4/11/2002	WIPO			
	ARR	WO 02/38162	5/16/2002	WIPO			
	ASS	WO 03/027147	4/3/2003	WIPO			
	ATT	WO 03/037932	5/8/2003	WIPO			
	AUU	WO 03/055512	7/10/2003	WIPO			
	AVV	WO 03/093465	11/13/2003	WIPO			
	AWW	WO 2004/029091	4/8/2004	WIPO			
	AXX	WO 2004/083361	9/30/2004	WIPO			
	AYY	EP 0 370 205	5/30/1990	EPO			
145	AZZ	EP 0 512 011	11/11/1992	EPO			

Examiner Signature	Date Considered
AM	9-5-06
EXAMINER: Initials citation considered. Draw line through citation if no	, , ,
next communication to applicant.	this combination and the control out this age copy of and forth that

Applicant	Application No. 10/031,005	Attorney's Docket No. 09531-016002	U.S. Department of Commerce Patent and Trademark Office	Substitute Form PTO-1449 (Moduled)
		Applicant Gary L. Nelsestuen	isclosure Statement Applicant	Vafamasian Di
by Applicant (Use several sheets if necessary) (37 CFR (98(b)) (37 CFR (98(b))) (38 CFR (98(b))) (39 CFR (98(b))) (37 CFR (98(b))) (38 CFR (98(b))) (39 CFR (98(b))) (39 CFR (98(b)))	, ·		I sheets if necessary)	(37 CFR 3).98(b))

	Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document				
ft5	AAAA	Bharadwaj et al., "Factor VII central. A novel mutation in the catalytic domain that reduces tissue factor binding, impairs activation by factor Xa, and abolishes amidolytic and coagulant activity," J. Biol. Chem., 1996, 271:30685-30691				
	ABBB	Bjoern et al., "Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine," J. Biol. Chem. 1991, 266(17):11051-11057				
	ACCC	Chang et al., "Engineered recombinant factor VII Q217 variants with altered inhibitor specificities," Biochemistry 1999, 38:10940-10948				
	ADDD	Chang et al., "Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B," J. Clin. Invest. 1997, 100(4), 886-892				
	AEEE	Cheung et al., "Localization of a metal-dependent epitope to the amino terminal residues 33-40 of human factor IX," Thrombosis Res. 1995, 80(5): 419-427				
	AFFF	EMBL Accession No. AF465270 (2/2/2003)				
	AGGG	UNIPROT Accession No. P22457 (8/1/1991)				
	АННН	Dickinson et al., "Influence of cofactor binding and active site occupancy on the conformation of the macromolecular substrate exosite of factor VIIa," J. Mol. Biol. 1998, 277:959-971				
	AIII	Dickinson et al., "Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa," Proc. Natl. Acad. Sci. 1996, 93:14379-14384				
	AJJJ	Hedner et al., "NovoSeven as a universal haemostatic agent," Blood Coagulation & Fibrinolysis 2000:11:107-111				
	AKKK	Higashi et al., "Molecular mechanism of tissue factor-mediated acceleration of factor VIIa activity," J. Biol. Chem. 1996, 271(43):26569-26574				
	ALLL	Huang et al., "Substrate Recognition by Tissue Factor-Factor VIIa. Evidence for interaction of residues Lys165 and Lys166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X" J. Biol. Chem. 1996, 271(36):21752-21757				
	AMMM	Iino et al., "Functional consequences of mutations in Ser-52 and Ser-60 in human blood coagulation factor VII," Archives of Biochemistry and Biophysics 1998, 352(2):182-192				
	ANNN	Iakhiaev et al., "The Role of Catalytic Cleft & Exosite Residues of Factor VIIa for Complex Formation with Tissue Factor Pathway Inhibitor" Thromobsis & Haemostasis 2001, 85:458-463				
	A000	Jin et al., "Factor VIIa's first epidermal growth factor-like domain's role in catalytic activity," Biochemistry 1999, 38:1185-1192				
	APPP	Jin et al., "Four loops of the catalytic domain of factor viia mediate the effect of the first EGF-like domain substitution on factor viia catalytic activity," J. Mol. Biol. 2001, 307:1503-1517				
	AQQQ	Kelly et al., "Ca ²⁺ binding to the first epidermal growth factor module of coagulation factor VIIa is important for cofactor interaction and proteolytic function," J. Biol. Chem. 1997, 272(28):17467-17472				
15	ARRR	Kemball-Cook et al., "Coagulation Factor VII Gln ¹⁰⁰ Arg. Amino acid substitution at the epidermal growth factor 2-protease domain interface results in severely reduced tissue factor binding and procoagulant function," J. Biol. Chem. 1998, 273(14):8516-8521				

Examiner Signature / / //	Date Considered			
Hully In	9-5-06			
EXAMINER: Initials digation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with				
next communication to applicarit.				
	Substitute Disclosure Form (PTO-1449)			

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 09531-016002	Application No. 10/031,005	
Information Disclosure Statement by Applicant		Applicant Gary L. Nelsestuen		
(Use several sheets if necessary)	Filing Date October 29, 2001	Group Art Unit		

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document		
HS	ASSS	Leonard et al., "Activation and Active Site Occupation Alter Conformation in the Region of the First Epidermal Growth Factor-like Domain of Human Factor VII," J. Biol. Chem. 2000, 275(45):34894-34900		
	ATTT	Mayer, "Ultra-early hemostatic therapy for intracerebral hemorrhage," Stroke 2003, 34:224-229		
	AUUU	Neuenschwander et al., "Alteration of the substrate and inhibitor specificities of blood coagulation," Biochemistry 1995, 34:8701-8707		
	AVVV	Persson et al., "Ca ²⁺ binding to the first epidermal growth factor-like domain of factor VIIa increases amidolytic activity and tissue factor affinity," J. Biol. Chem. 1997, 272(32):19919-19924		
	AWWW	Persson, "Characterization of the interaction between the light chain of factor VIIa and tissue factor," FEBS Letters 1997, 413:359-363		
	AXXX	Petersen et al., "Binding of Zn ²⁺ to a Ca ²⁺ loop allosterically attenuates the activity of factor VIIa and reduces its affinity for tissue factor," Protein Science 2000, 9:859-866		
	AYYY	Petrovan et al., "Role of residue Phe ²²⁵ in the cofactor-mediated, allosteric regulation of the serine protease coagulation factor VIIa," Biochemistry 2000, 39:14457-14463		
	AZZZ	Petrovan et al., "Residue Met ¹⁵⁶ contributes to the labile enzyme conformation of coagulation factor VIIa," J. Biol. Chem. 2001, 276(9):6616-6620		
	AAAAA	Shobe et al., "Regulation of the catalytic function of coagulation factor VIIa by a conformational linkage of surface residue Glu 154 to the active site," Biochemistry 1999, 38:2745-2751		
	ABBBB	Shobe et al., "Macromolecular substrate affinity for the tissue factor-factor VIIa complex is independent of scissile bond docking," J. Biol. Chem. 1999, 274(34):24171-24175		
	ACCCC	Sridhara et al., "Activation of a recombinant human factor VII structural analogue alters its affinity of binding to tissue factor," Amer. J. Hemotology 1996, 53:66-71		
13	ADDDD	Zhang et al., "Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant," J. Mol. Biol. 1999, 285(5):2089-2104		

Examiner Signature	Date Considered	
La July Do	9-5-06	
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		